End-of-life care: A retrospective study comparing sarcoma and patients with carcinoma [0.03%]
终末期癌症患者的护理回顾性研究——肉瘤与腺癌患者的比较
Luca Zambelli,Giacomo Massa,Francesca Ricchini et al.
Luca Zambelli et al.
Background: Soft tissue and bone sarcomas may carry a considerable symptom burden, which typically worsens in the final weeks of life. To help clarify personalized palliative care needs, we investigated discrepancies in e...
A practical framework of preoperative imaging for non-small cell lung cancer: Thoracic surgeons' expectations from radiologists [0.03%]
非小细胞肺癌的术前影像检查实用框架：胸外科医师对放射科医师的期待
Ulas Kumbasar,Gamze Durhan
Ulas Kumbasar
Accurate preoperative imaging is essential for determining operability, guiding surgical planning, and optimizing outcomes in the treatment of non-small cell lung cancer (NSCLC). This paper outlines thoracic surgeons' expectations from radi...
Multiparametric whole-body magnetic resonance imaging in breast cancer management: A prospective study [0.03%]
乳腺癌治疗中多参数全身磁共振成像的前瞻性研究
Michela Palleschi,Filippo Merloni,Andrea Prochowski Iamurri et al.
Michela Palleschi et al.
Multiparametric Whole-Body Magnetic Resonance Imaging (WB-MRI) may enhance bone metastasis detection in metastatic breast cancer (mBC) patients. We report preliminary results from a prospective clinical trial investigating WB-MRI utility in...
Alectinib and gastrointestinal perforation in ALK-rearranged non-small cell lung cancer: A case series [0.03%]
Alecitinib治疗间变性淋巴瘤激酶重排非小细胞肺癌的胃肠穿孔不良反应的病例系列分析
Margherita Piccinelli,Raffaele Squitieri,Rebecca Romanò et al.
Margherita Piccinelli et al.
Background: Alectinib, a second-generation ALK inhibitor, is used in first-line and adjuvant treatment for ALK-rearranged NSCLC, and has proven to be both effective and well tolerated. Gastrointestinal (GI) perforation is...
Effectiveness of carboplatin vs cisplatin in lung cancer chemo-immunotherapy: A systematic review and meta-analysis [0.03%]
卡铂与顺铂在肺癌化疗免疫治疗中的有效性比较：系统评价和 Meta 分析
Alessandro Leonetti,Giuseppe Maglietta,Marianna Peroni et al.
Alessandro Leonetti et al.
IntroductionChemo-immunotherapy (CT-IT) currently represents the standard therapy for both non-small (NSCLC) and small cell lung cancer (SCLC). However, the differential impact of platinum compounds on immunotherapy outcomes remains to be d...
Hospice admission of cancer patients receiving disease-modifying therapies near the end of life: implications for eligibility criteria [0.03%]
晚期接受疾病修正治疗的癌症患者入住安宁疗护病房的状况及其对纳入标准的意义
Carla Bettini,Andrea Carlini,Laura Fabbri et al.
Carla Bettini et al.
Purpose: This retrospective single-center observational study aimed to describe our experience of admitting patients based on palliative care needs rather than discontinuation of anticancer treatment. ...
Exploring new frontiers: Outcomes and feasibility of a third radiotherapy course in recurrent prostate cancer [0.03%]
探索新领域：复发性前列腺癌第三程放射治疗的有效性和可行性
Costantino Putzu,Federico Mastroleo,Mattia Zaffaroni et al.
Costantino Putzu et al.
Background and purpose: Re-irradiation is increasingly recognized as a viable and safe treatment option for prostate cancer (PCa) local recurrence. The aim of this study is to present the safety profile, feasibility, and ...
Ewing sarcoma of the head and neck region in pediatric patients: A retrospective monoinstitutional series [0.03%]
儿童头颈部尤文肉瘤的单中心回顾性系列研究
Valentina Di Ruscio,Ida Russo,Angela Di Giannatale et al.
Valentina Di Ruscio et al.
Ewing sarcoma (ES) occurs in the head and neck (HN) region in fewer than 10% of cases, presenting distinct therapeutic challenges.We retrospectively reviewed all ES cases diagnosed at our institution from 2000 to 2022.Of 131 patients, 10 (7...
The landscape of artificial intelligence in carbon ion radiotherapy: A scoping review [0.03%]
碳离子放射治疗领域的人工智能现状：系统综述
Giulia Fontana,Sithin Thulasi Seetha,Sara Lillo et al.
Giulia Fontana et al.
Objective: While artificial intelligence (AI) is known to benefit radiotherapy (RT), its applications in carbon ion RT (CIRT) is yet to be surveyed. This scoping review aims to examine the current landscape of AI in CIRT ...
Modern approaches to target tumor heterogeneity: Integrating technology and treatment [0.03%]
针对肿瘤异质性的现代方法：技术与治疗的整合
Amit Kumar,Nisha Manav,Mayank Singh et al.
Amit Kumar et al.
Intratumor heterogeneity (ITH) describes the diversity of cancer cells within a single tumor. This heterogeneity includes differences in the cells' phenotypes, genotypes, and functions. As a result, cancer cells can vary in their morphology...